Key Takeaways
- • Canadian venture capital investment collapsed to CAD $2.9 billion across 254 deals in H1 2025, the lowest first-half total since 2020 and representing a 26% decline in dollars invested and 22% drop in deal count year-over-year.
- • Early-stage funding shows acute stress: pre-seed and seed deals deployed only CAD $297 million across 133 transactions, accounting for 52% of deal count but just 10% of total invested capital, signaling compressed valuations and limited appetite for early-stage risk.
- • Investors are executing a strategic pivot toward larger, more selective investments—average deal size remained steady at CAD $11.4 million—while new capital deployment patterns favor life sciences strength, venture debt surge, and secondary market utilization.
- • The market contraction reflects structural adjustment in Canada's VC ecosystem, with CVCA noting a "period of adjustment" characterized by more selective capital deployment, particularly at the critical earliest investment stages.
Summary
Canadian venture capital markets have contracted sharply in the first half of 2025, hitting pandemic-era lows that signal a fundamental recalibration across the investment landscape. According to the Canadian Private Equity Association (CVCA), a total of CAD $2.9 billion was deployed across 254 deals—the lowest H1 aggregate since 2020. This marks a 26% decline in total dollars invested and a 22% reduction in deal count compared to H1 2024, indicating a broad-based pullback in VC activity.
The contraction is most pronounced in early-stage funding, where pre-seed and seed activity has deteriorated significantly. These nascent stages attracted only CAD $297 million across 133 completed transactions, representing 52% of total deal activity but accounting for merely 10% of deployed capital. This bifurcation reveals a market increasingly bifurcated between well-capitalized late-stage companies and underfunded early-stage ventures. The compressed early-stage economics reflect both limited investor appetite for early-stage risk and significant downward pressure on startup valuations.
Despite the overall contraction, pockets of resilience persist. The average deal size held firm at CAD $11.4 million, suggesting that institutional investors continue to back proven companies and founding teams, albeit with greater selectivity. Life sciences has emerged as a relative bright spot, while venture debt activity has surged as an alternative capital mechanism. Additionally, secondary market transactions have gained traction, enabling earlier investors to achieve liquidity exits without reliance on traditional exit pathways.
David Kornacki, Director of Data & Product at CVCA, characterized the environment as one of deliberate market adjustment. "Canada's venture capital ecosystem is holding steady through a period of adjustment," Kornacki stated, emphasizing that "we are seeing more selective deployment of capital, especially at the critical earliest stages of investment." The utilization of secondaries alongside increased venture debt activity underscores how institutional allocators are adapting to a more challenging fundraising and exit environment.
The H1 2025 results reflect structural headwinds in the Canadian VC market rather than cyclical volatility alone. With CVCA representing over 340 member firms and 2,600 industry leaders, the organization's data provides comprehensive market visibility. The persistence of subdued early-stage activity, combined with observable investor preference for larger, de-risked transactions, suggests that capital reallocation toward proven business models will likely persist absent significant macroeconomic shifts or renewed institutional appetite for early-stage deployment.
The contraction is most pronounced in early-stage funding, where pre-seed and seed activity has deteriorated significantly. These nascent stages attracted only CAD $297 million across 133 completed transactions, representing 52% of total deal activity but accounting for merely 10% of deployed capital. This bifurcation reveals a market increasingly bifurcated between well-capitalized late-stage companies and underfunded early-stage ventures. The compressed early-stage economics reflect both limited investor appetite for early-stage risk and significant downward pressure on startup valuations.
Despite the overall contraction, pockets of resilience persist. The average deal size held firm at CAD $11.4 million, suggesting that institutional investors continue to back proven companies and founding teams, albeit with greater selectivity. Life sciences has emerged as a relative bright spot, while venture debt activity has surged as an alternative capital mechanism. Additionally, secondary market transactions have gained traction, enabling earlier investors to achieve liquidity exits without reliance on traditional exit pathways.
David Kornacki, Director of Data & Product at CVCA, characterized the environment as one of deliberate market adjustment. "Canada's venture capital ecosystem is holding steady through a period of adjustment," Kornacki stated, emphasizing that "we are seeing more selective deployment of capital, especially at the critical earliest stages of investment." The utilization of secondaries alongside increased venture debt activity underscores how institutional allocators are adapting to a more challenging fundraising and exit environment.
The H1 2025 results reflect structural headwinds in the Canadian VC market rather than cyclical volatility alone. With CVCA representing over 340 member firms and 2,600 industry leaders, the organization's data provides comprehensive market visibility. The persistence of subdued early-stage activity, combined with observable investor preference for larger, de-risked transactions, suggests that capital reallocation toward proven business models will likely persist absent significant macroeconomic shifts or renewed institutional appetite for early-stage deployment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.